Company Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer.
Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.
It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer.
Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Barbara Weber |
Contact Details
Address: 201 Brookline Avenue, Suite 901 Boston, Massachusetts 02215 United States | |
| Phone | 857 320 4900 |
| Website | tangotx.com |
Stock Details
| Ticker Symbol | TNGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819133 |
| CUSIP Number | 87583X109 |
| ISIN Number | US87583X1090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Barbara L. Weber M.D. | President, Chief Executive Officer and Director |
| Dr. Adam S. Crystal M.D., Ph.D. | President of Research and Development |
| Dr. Alan Ashworth FRS, Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Levi Garraway M.D., Ph.D. | Founder |
| Dr. William G. Kaelin Jr., M.D. | Founder and Member of Scientific Advisory Board |
| Dr. Timothy K. Lu M.D., Ph.D. | Founder |
| Dr. Antoni Ribas M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
| Timothy Redfern | Chief Financial Officer |
| Dr. Michael Palmieri Ph.D. | Head of Technical Operations |
| Jannik N. Andersen Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 6, 2024 | 144 | Filing |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 28, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 25, 2024 | 144 | Filing |
| Oct 22, 2024 | 144 | Filing |
| Oct 22, 2024 | 144 | Filing |
| Oct 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |